Abstract
Tumor development is often associated with a deep alteration of normal myelopoiesis, leading to a progressive accumulation of various cellular elements, belonging to myelomonocytic lineage, in the tumor bed, in the blood, and in both primary and secondary lymphoid organs. This heterogeneous pool of cells expresses, in the mouse, the common markers CD11b and Gr-1 (Ly6C/G) and is endowed with the ability to suppress antigen and/or polyclonal-driven T cell immune response. These cells, named myeloid-derived suppressor cells (MDSCs), are mobilized from hematopoietic organs by cytokines and other factors produced by the tumors, as well as by strong activation of the immune system, and have a profound influence on the outcome of the T cell-dependent immune responses. MDSCs can restrain T cell function directly in an antigen-independent manner; however, in vivo, MDSCs can also process and present tumor-associated antigen and can lead to T cell tolerance in an antigen-specific manner. Furthermore, MDSCs seem to be key players in tumor-induced suppressive network that includes T regulatory (Treg) cells, inhibitory natural killer T (NKT) cells, mast cells, Th17, as well as effector T cells. The importance of MDSCs in human malignancies has been demonstrated in recent years and new approaches targeting their suppressive/tolerogenic action are currently being tested in both preclinical model and clinical trials.
| Original language | English (US) |
|---|---|
| Title of host publication | Tumor-Induced Immune Suppression: Mechanisms and Therapeutic Reversal |
| Publisher | Springer New York |
| Pages | 99-150 |
| Number of pages | 52 |
| Volume | 9781489980564 |
| ISBN (Print) | 9781489980564, 1489980555, 9781489980557 |
| DOIs | |
| State | Published - Feb 1 2014 |
Fingerprint
Keywords
- Clinical trials
- Human myeloid derived suppressor cells
- MDSC phenotype
- Mechanisms of action
- Mouse myeloid derived suppressor cells
- Tumor derived factors
- Tumor progression
ASJC Scopus subject areas
- Medicine(all)
Cite this
Myeloid-derived suppressor cells in tumor-induced T cell suppression and tolerance. / Serafini, Paolo; Bronte, Vincenzo.
Tumor-Induced Immune Suppression: Mechanisms and Therapeutic Reversal. Vol. 9781489980564 Springer New York, 2014. p. 99-150.Research output: Chapter in Book/Report/Conference proceeding › Chapter
}
TY - CHAP
T1 - Myeloid-derived suppressor cells in tumor-induced T cell suppression and tolerance
AU - Serafini, Paolo
AU - Bronte, Vincenzo
PY - 2014/2/1
Y1 - 2014/2/1
N2 - Tumor development is often associated with a deep alteration of normal myelopoiesis, leading to a progressive accumulation of various cellular elements, belonging to myelomonocytic lineage, in the tumor bed, in the blood, and in both primary and secondary lymphoid organs. This heterogeneous pool of cells expresses, in the mouse, the common markers CD11b and Gr-1 (Ly6C/G) and is endowed with the ability to suppress antigen and/or polyclonal-driven T cell immune response. These cells, named myeloid-derived suppressor cells (MDSCs), are mobilized from hematopoietic organs by cytokines and other factors produced by the tumors, as well as by strong activation of the immune system, and have a profound influence on the outcome of the T cell-dependent immune responses. MDSCs can restrain T cell function directly in an antigen-independent manner; however, in vivo, MDSCs can also process and present tumor-associated antigen and can lead to T cell tolerance in an antigen-specific manner. Furthermore, MDSCs seem to be key players in tumor-induced suppressive network that includes T regulatory (Treg) cells, inhibitory natural killer T (NKT) cells, mast cells, Th17, as well as effector T cells. The importance of MDSCs in human malignancies has been demonstrated in recent years and new approaches targeting their suppressive/tolerogenic action are currently being tested in both preclinical model and clinical trials.
AB - Tumor development is often associated with a deep alteration of normal myelopoiesis, leading to a progressive accumulation of various cellular elements, belonging to myelomonocytic lineage, in the tumor bed, in the blood, and in both primary and secondary lymphoid organs. This heterogeneous pool of cells expresses, in the mouse, the common markers CD11b and Gr-1 (Ly6C/G) and is endowed with the ability to suppress antigen and/or polyclonal-driven T cell immune response. These cells, named myeloid-derived suppressor cells (MDSCs), are mobilized from hematopoietic organs by cytokines and other factors produced by the tumors, as well as by strong activation of the immune system, and have a profound influence on the outcome of the T cell-dependent immune responses. MDSCs can restrain T cell function directly in an antigen-independent manner; however, in vivo, MDSCs can also process and present tumor-associated antigen and can lead to T cell tolerance in an antigen-specific manner. Furthermore, MDSCs seem to be key players in tumor-induced suppressive network that includes T regulatory (Treg) cells, inhibitory natural killer T (NKT) cells, mast cells, Th17, as well as effector T cells. The importance of MDSCs in human malignancies has been demonstrated in recent years and new approaches targeting their suppressive/tolerogenic action are currently being tested in both preclinical model and clinical trials.
KW - Clinical trials
KW - Human myeloid derived suppressor cells
KW - MDSC phenotype
KW - Mechanisms of action
KW - Mouse myeloid derived suppressor cells
KW - Tumor derived factors
KW - Tumor progression
UR - http://www.scopus.com/inward/record.url?scp=84930023844&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84930023844&partnerID=8YFLogxK
U2 - 10.1007/978-1-4899-8056-4_4
DO - 10.1007/978-1-4899-8056-4_4
M3 - Chapter
AN - SCOPUS:84930023844
SN - 9781489980564
SN - 1489980555
SN - 9781489980557
VL - 9781489980564
SP - 99
EP - 150
BT - Tumor-Induced Immune Suppression: Mechanisms and Therapeutic Reversal
PB - Springer New York
ER -